Clinical Trials Logo

Filter by:
NCT ID: NCT06052098 Recruiting - Clinical trials for Stage IA Lung Cancer

Transbronchial vs Transthoracic Ablation for Early-stage Peripheral Lung Cancer

Start date: October 11, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of RFA through a transthoracic or transbronchial approach in the treatment of early-stage peripheral lung cancer.

NCT ID: NCT06052033 Recruiting - HPV Infection Clinical Trials

Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection

Start date: September 11, 2023
Phase: N/A
Study type: Interventional

Non-RCT clinical trial comparing 5-ALA photodynamic therapy and CO2 laser for persistent high-risk HPV-related low-grade cervical lesions.

NCT ID: NCT06052020 Recruiting - Stroke Clinical Trials

Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study

EAST-sICAS
Start date: September 15, 2023
Phase:
Study type: Observational

The primary goal of the trial is to investigate whether the lipid lowering strategy using Alirocumab plus statin could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 6 months of follow-up, in patients with recent stroke/transient ischemic attack (TIA) caused by intracranial artery stenosis.

NCT ID: NCT06051929 Not yet recruiting - Emotional Distress Clinical Trials

Mechanism of Mindfulness Intervention for Emotional Distress: the Role of Cognitive Flexibility

Start date: October 20, 2023
Phase: N/A
Study type: Interventional

This study hopes to: explore whether offline and online mindfulness interventions can significantly alleviate individual emotional distress and improve cognitive flexibility level. explore whether cognitive flexibility is a mediator in mindfulness intervention to alleviate emotional distress, and to meet the principles of mechanism.

NCT ID: NCT06051851 Recruiting - Clinical trials for Pancreatic Adenocarcinoma Metastatic

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

RCT-PAAG
Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-center, open-label, randomized controlled Phase II clinical study to observe and evaluate the efficacy and safety of Penpulimab combined with Anlotinib and Nab-paclitaxel plus Gemcitabine (PAAG ) versus AG first-line treatment in patients with metastatic pancreatic cancer.

NCT ID: NCT06051838 Completed - Clinical trials for Exploring the Prognostic Value of Tumor Deposits PTC Patients

Prognostic Value of Tumor Deposits for Patients With Papillary Thyroid Carcinoma

Start date: November 1, 2022
Phase:
Study type: Observational

Tumor deposits (TD), nodules in the peritumoral adipose tissue with no architectural residue of lymph node, which is a definition often being confusing to the extranodal extension (ENE), have been described in several malignancies and linked to a worse prognosis. In gastric cancer and colon cancer, TD and ENE should be distinguished and collected separately in 8th AJCC manual. However, in thyroid cancer, TD as a collection variable was absence in both the 8th AJCC manual and the 2015 ATA guideline. This is a study that revealed the presence of TD by reviewing a large number of papillary thyroid carcinoma (PTC) specimens and explored its prognostic value by constructing a nomogram to accurately predict disease-free survival in PTC patients.

NCT ID: NCT06051760 Not yet recruiting - Malignant Neoplasm Clinical Trials

NV-001 in the Treatment of Advanced Solid Tumors

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors.

NCT ID: NCT06051565 Completed - Diabetes Clinical Trials

Cardiovascular Contrast-enhanced Magnetic Resonance Imaging Using Polysaccharide Superparamagnetic Iron Oxide Injection in Diabetic Patients

Start date: November 6, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, single-center, single-dose study aims to evaluate the effect and safety of polymeric superparamagnetic iron oxide in cardiovascular magnetic resonance imaging for diabetic patients with concomitant chronic kidney disease.

NCT ID: NCT06051552 Not yet recruiting - Moyamoya Disease Clinical Trials

Prognostic Prediction Model in Patients With Moyamoya Disease Undergoing Revascularization Surgery

Start date: October 1, 2023
Phase:
Study type: Observational

Moyamoya Disease (MMD) is a rare chronic cerebrovascular disease characterized by progressive occlusion of the internal carotid artery or its major branches, with blood flow compensated by the formation of an abnormal vascular network (smoky). According to the latest national epidemiological survey in 2022, the cumulative number of new cases in the population was 47,443 in two years, with the annual incidence rate increasing year by year. The first symptoms are mainly cerebral infarction, transient ischemic attack, intracranial hemorrhage, and epileptic seizure, and the onset of the disease is concentrated in the age group of 45-54 years old, which is one of the most important causes of new strokes in middle-aged and young people and imposes a heavy medical burden on the society and the family. As one of the major causes of new strokes in young and middle-aged people, it brings a heavy medical burden to society and families. Hemodialysis has been confirmed as a standard treatment for patients with smokers' disease in large sample studies to prevent bleeding and recurrence of hemorrhage; however, there is no better consensus on which anesthetic technique to use for hemodialysis in patients with MMD. Currently, the more perfect prediction model is the postoperative collateral compensation formation prediction model for direct and indirect hemodialysis, which has the advantage of making full use of the patients' preoperative baseline variables and imaging characteristics, but the relatively insufficient inclusion of the sample size and the lack of intraoperative (vital signs, respiratory parameters, local cerebral oxygenation, etc.) and postoperative (postoperative neurological injury markers, etc.) variables included in the model limits the clinical scenarios. The lack of intraoperative (vital signs, respiratory parameters, local cerebral oxygen saturation) and postoperative (postoperative neurologic injury markers) variables limits the clinical application scenarios and is unable to guide the clinical decision-making and prognosis in the important stages of the perioperative period. This study aims to establish a prospective cohort database for MMD hemodialysis that includes perioperative anesthesia management, intraoperative treatment data, and postoperative treatment variables; to integrate preoperative, intraoperative, postoperative, and near- and long-term prognostic data from multiple sources, and to construct a perioperative multi-stage, multi-dimensional prognostic prediction model.

NCT ID: NCT06051513 Recruiting - Clinical trials for Carbapenem-Resistant Enterobacteriaceae Infection

Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection

Start date: September 21, 2023
Phase: N/A
Study type: Interventional

Colistin can be used to treat the infection caused by carbapenem-resistant enterobacteriaceae(CRE). In China, patients diagnosed with Hospital-acquired-pneumonia (HAP)or bloodstream infection caused by CRE are recruited, and randomly assigned to two groups, and in one group the patients accept treatment with colistin, however in another group, the patients accept treatment without colistin. The efficacy and safety of the treatment between the two groups are compared.